We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ARES:NYSEAres Management Corporation Analysis

Data as of 2026-03-10 - not real-time

$110.17

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Ares Management is trading well below its short‑term, mid‑term and long‑term moving averages, indicating a bearish price environment. The relative strength index sits in oversold territory, suggesting potential for a short‑term bounce. Momentum indicators show a nascent bullish signal as the MACD line has crossed above its signal line. Volume has been trending down, which tempers the upside potential of any rebound. The stock benefits from a dividend yield that is among the highest in the financial services sector. However, the payout ratio is well above sustainable levels, raising concerns about dividend continuity.
Fundamentals reveal solid revenue growth and a recent acquisition that expands the firm’s direct‑lending platform. The company’s debt load is substantial, resulting in a leverage profile that exceeds typical asset‑manager norms. A discounted cash‑flow model places intrinsic value considerably above the current market price, implying a sizable upside. Analyst consensus remains bullish, with target prices well above today’s level. The firm’s exposure to emerging sectors such as artificial intelligence adds a growth catalyst for the medium to long term. Given the blend of valuation disparity, dividend appeal, and strategic positioning, the outlook leans toward a gradual price recovery.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near strong support level
  • oversold momentum indicator
  • decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • discounted cash‑flow upside
  • strategic acquisition expanding lending platform
  • high dividend yield despite sustainability concerns

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • significant intrinsic value gap
  • exposure to growth areas such as AI
  • potential for dividend normalization as earnings improve

Key Metrics & Analysis

Financial Health

Revenue Growth19.50%
Profit Margin9.41%
P/E Ratio64.4
ROE13.52%
ROA2.34%
Debt/Equity163.45
P/B Ratio8.7
Op. Cash Flow$3.3B
Free Cash Flow$2.0B
Industry P/E17.4

Technical Analysis

TrendBearish
RSI32.4
Support$105.48
Resistance$140.99
MA 20$121.44
MA 50$143.58
MA 200$161.96
MACDBullish
VolumeDecreasing
Fear & Greed Index80.79

Valuation

Fair Value$149.51
Target Price$167.94
Upside/Downside52.44%
GradeUndervalued
TypeBlend
Dividend Yield4.96%

Risk Assessment

Beta1.67
Volatility67.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.